PLUR
Price
$3.96
Change
-$0.35 (-8.12%)
Updated
Jun 20 closing price
Capitalization
31.18M
RNA
Price
$29.32
Change
-$0.00 (-0.00%)
Updated
Jun 20 closing price
Capitalization
3.53B
52 days until earnings call
Interact to see
Advertisement

PLUR vs RNA

Header iconPLUR vs RNA Comparison
Open Charts PLUR vs RNABanner chart's image
Pluri
Price$3.96
Change-$0.35 (-8.12%)
Volume$140.43K
Capitalization31.18M
Avidity Biosciences
Price$29.32
Change-$0.00 (-0.00%)
Volume$1.51M
Capitalization3.53B
PLUR vs RNA Comparison Chart in %
Loading...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLUR vs. RNA commentary
Jun 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLUR is a Hold and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 21, 2025
Stock price -- (PLUR: $3.96 vs. RNA: $29.32)
Brand notoriety: PLUR and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLUR: 554% vs. RNA: 105%
Market capitalization -- PLUR: $31.18M vs. RNA: $3.53B
PLUR [@Biotechnology] is valued at $31.18M. RNA’s [@Biotechnology] market capitalization is $3.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $333.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLUR’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • PLUR’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both PLUR and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNA’s TA Score shows that 4 TA indicator(s) are bullish.

  • RNA’s TA Score: 4 bullish, 6 bearish.

Price Growth

PLUR (@Biotechnology) experienced а -9.97% price change this week, while RNA (@Biotechnology) price change was -6.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.70%. For the same industry, the average monthly price growth was +28.03%, and the average quarterly price growth was +14.56%.

Reported Earning Dates

PLUR is expected to report earnings on May 13, 2025.

RNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.53B) has a higher market cap than PLUR($31.2M). RNA YTD gains are higher at: 0.825 vs. PLUR (-7.336). PLUR has higher annual earnings (EBITDA): -20.22M vs. RNA (-430.35M). RNA has more cash in the bank: 1.38B vs. PLUR (26.3M). RNA has less debt than PLUR: RNA (5.97M) vs PLUR (31.2M). RNA has higher revenues than PLUR: RNA (8.93M) vs PLUR (1.03M).
PLURRNAPLUR / RNA
Capitalization31.2M3.53B1%
EBITDA-20.22M-430.35M5%
Gain YTD-7.3360.825-889%
P/E RatioN/AN/A-
Revenue1.03M8.93M12%
Total Cash26.3M1.38B2%
Total Debt31.2M5.97M522%
FUNDAMENTALS RATINGS
PLUR: Fundamental Ratings
PLUR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNA
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPCCX4.00N/A
N/A
Comstock Capital Value C
HGOIX65.87N/A
N/A
Hartford Growth Opportunities I
FIIMX22.98N/A
N/A
Fidelity Advisor Mid Cap II I
PRPAX5.90N/A
N/A
PGIM Jennison Energy Infrastructure A
ETLNX14.53N/A
N/A
Eventide Large Cap Focus N